索拉非尼治疗肾癌脑转移的疗效及安全性  

Efficacy and Safety of Sorafenib in Patients with Renal Cell Carcinoma Brain Metastases

作　　者：杨琳[1] 丁英俊[2] 石磊[1] 于世英[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院肿瘤科,武汉430030 [2]华中科技大学同济医学院附属同济医院老年科,武汉430030

出　　处：《医药导报》2012年第10期1318-1321,共4页Herald of Medicine

基　　金：湖北省自然科学基金资助项目(2011CDB213)

摘　　要：目的观察索拉非尼治疗肾癌脑转移(RCCBM)的疗效及安全性。方法回顾性分析使用索拉非尼治疗的RCCBM病例,观察不良反应发生的种类、程度和治疗转归,以及临床疗效。结果 7例RCCBM患者服用索拉非尼治疗,最常见的不良反应为手足综合征、腹泻、皮疹、高血压、疲乏和脱发,大多为轻至中度,处理后转归良好,无颅内出血等严重不良反应发生。疾病控制率为57.1%,中位无疾病进展时间为5个月,中位总生存为16个月。结论索拉非尼治疗RCCBM的安全性良好,在局部治疗后使用可获得长期临床获益。Objective To evaluate safety and efficacy of sorafenib in patients with renal cell carcinoma brain metastases（RCCBM）.Methods Sorafenib-related adverse events and the clinical efficacy in RCCBM patients were retrospectively analyzed.The category,severity and turnover of sorafeinb-related adverse events were observed.Also,the disease control rate（DCR）,progression-free survival（PFS） and overall survival（OS） were analyzed.Results In the seven RCCBM patients treated with sorafenib,the most common adverse events were hand-foot syndrome,diarrhea,rash,hypertension,fatigue and alopecia.Most of the adverse events happened in mild to moderate degree,and were alleviated after corresponding treatment.No severe adverse events like intracranial hemorrhage happened.The DCR,median progress free survival and median overall survival were 57.1%,5 months and 16 months,respectively.Conclusion The safety of sorafenib in RCCBM patients is satisfying.After local treatment,patients can obtain long-term clinical benefit from sorafenib treatment.

关 键 词：索拉非尼 肾癌脑转移 靶向治疗 

分 类 号：R979.1[医药卫生—药品] R737.11[医药卫生—药学]